The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Open accessAbstract
BACKGROUND Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy. METHODS In this population-based study, we analysed patients who received second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada, USA, Greece, Japan, Singapore, South Korea, and Denmark. The primary endpoint was overall survival since the initiation of second-line therapy. We compared the prognostic performance of the IMDC model with the three-factor MSKCC model used for previously treated patients for overall survival since the start of second-line targeted therapy. FINDINGS Between Jan 1, 2005, and Nov 30, 2012, we included 1021 patients treated with second-line targeted therapy. Median overall survival since the start of second-line targeted therapy was 12·5 months (95% CI 11·3-14·3). Five of six predefined factors in the IMDC model (anaemia, thrombocytosis, neutrophilia, Karnofsky performance status [KPS] <80, and <1 year from diagnosis to first-line targeted therapy) were independent predictors of poor overall survival on multivariable analysis. The concordance index using all six prognostic factors (ie, also including hypercalcaemia) was 0·70 (95% CI 0·67-0·72) with the IMDC model and was 0·66 (95% CI 0·64-0·68) with the three-factor MSKCC model. When patients were divided into three risk categories using IMDC criteria, median overall survival was 35·3 months (95% CI 28·3-47·8) in the favourable risk group (n=76), 16·6 months (14·9-17·9) in the intermediate risk group (n=529), and 5·4 months (4·7-6·8) in the poor risk group (n=261). INTERPRETATION The IMDC prognostic model can be applied to patients previously treated with targeted therapy, in addition to previously validated populations in first-line targeted therapy. The IMDC prognostic model in the second-line targeted therapy setting has an improved prognostic performance and is applicable to a more contemporary patient cohort than that of the three-factor MSKCC model. FUNDING DF/HCC Kidney Cancer SPORE P50 CA101942-01, Kidney Cancer Research Network of Canada, Canadian Institute for Health Research, Trust Family, Loker Pinard, Michael Brigham, and Gerald DeWulf.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Self-citationPazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Self-citationRini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Self-citationRegression modelling strategies for improved prognostic prediction
Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,798
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
Heng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Self-citation
Cited by
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bedke, J., Capitanio, U., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.03.006 · Cited by 1,508
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bensalah, K., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.011 · Cited by 1,456
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationTreatment of renal cell carcinoma: Current status and future directions
Barata, P. C., & Rini, B. I. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21411 · Cited by 831
Self-citation
Metadata
- Authors
- Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., Smoragiewicz, M., Donskov, F., Kanesvaran, R., Wood, L., Ernst, D. S., Agarwal, N., Vaishampayan, U. N., Rha, S.-Y., Choueiri, T. K., & Heng, D. Y. C.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 293-300
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2140116071
- Cited by
- 382
- References
- 24
- FWCI
- 29.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71222-7
- The paper
- Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., Smoragiewicz, M., Donskov, F., Kanesvaran, R., Wood, L., Ernst, D. S., Agarwal, N., Vaishampayan, U. N., Rha, S.-Y., Choueiri, T. K., & Heng, D. Y. C. (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71222-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.